- Pfizer Ltd is the Indian arm of one of the world’s largest biopharmaceutical companies, operating in the country since 1950 - the same year India adopted its Constitution. It began by manufacturing anti-tuberculosis drugs and pioneering large-scale antibiotic production, and over 75 years has built a portfolio of household names like Becosules and Corex alongside cutting-edge global medicines. The recurring approach is a deliberate pivot from legacy domestic brands toward innovative therapies from its parent’s pipeline, raising the share of global brands in its mix from 36.3% in 2016 to nearly half.
Business segments
One business - pharmaceuticals - organised into four therapeutic engines that share a common manufacturing backbone and a parent company’s pipeline, each attacking a different part of the patient journey: prevention, chronic care, hospital infection, and autoimmune disease.
1. Vaccines: the prevention franchise that leads India’s private market
A single pneumococcal vaccine, Prevenar 13, commands more than half the private market and anchors a business built on life-course vaccination - from infants to the elderly.
- The flagship is a market leader - Prevenar 13 is India’s first and only pneumococcal conjugate vaccine approved for all age groups, from six-week-old infants to the elderly, and held a 46.2% unit share and 62.5% value share of the private pneumococcal vaccines market as of March 2023. It is the number-one vaccine by revenue in India’s private vaccine market.
- A next-generation shot expands the adult franchise - Prevenar 20, a 20-valent vaccine for adults launched in August 2025, protects against 20 strains of the pneumonia-causing bacterium and captured 12.1% value share within months, ranking among India’s top two new pharmaceutical launches that year.
- Demand is built through hospital partnerships, not just doctor prescriptions - the company sets up Centres of Excellence for adult vaccination inside corporate hospitals and runs the Duty@50 initiative, which has vaccinated over 190,000 adults by working with more than 20 corporates, two insurers, and 10-plus hospitals.
- A digital funnel turns awareness into appointments - a 100% digital patient journey for Prevenar 13 reached 8 million people and drove engagement with 30,000 consumers, while a partnership with a leading e-pharmacy tapped a pool of 500,000 patients with co-morbid conditions to push vaccination fulfilment.
2. Internal Medicine: the chronic-care portfolio that reaches the mass market
A collection of legacy and global brands spanning cardiology, women’s health, vitamins, gastroenterology, pain, and neuroscience - increasingly distributed through partners rather than its own sales force.
- The blood-thinner that beat generics - Eliquis, an oral anticoagulant, retained its position as the number-one novel oral anticoagulant in its represented market with a 35% share in FY25, even after losing patent protection in 2022 and facing more than 100 generic competitors. It achieved this by expanding its prescriber base by roughly 5,000 doctors and growing patient reach approximately threefold post-loss-of-exclusivity.
- A 60-year-old vitamin brand still gaining share - Becosules, the number-one selling vitamin B-complex brand in India, contributes over 75% of the vitamins franchise sales and gained one percentage point of market share in a category worth about ₹3,000 Crore. It is now distributed through a technology-enabled partnership with GoApptiv rather than solely through Pfizer’s own field force.
- Handing distribution to Cipla for wider reach - in December 2025, Pfizer signed a five-year deal giving Cipla the sole right to market, distribute, and sell four established brands - Corex Dx (the dry-cough market leader with a 15% value share), Corex LS, Dolonex, and Neksium - while Pfizer continues to manufacture them. The logic is to leverage Cipla’s broader network, especially in Tier-2 cities and beyond.
- A new migraine drug opens a neuroscience front - Nurtec ODT, a first-of-its-kind orally disintegrating tablet for acute migraine, was launched targeting the CGRP pathway and is already onboarding over 500 new patients per month in its early growth phase. It avoids the blood-vessel constriction that makes older migraine drugs risky for patients with cardiovascular conditions.
- Women’s health runs on trusted staples - the portfolio leads the folic-acid market with a 24% share and holds second place in combined oral contraceptives at 19%, anchored by Folvite (a top-five prescribed brand among gynaecologists) and Ovral L, the most prescribed oral contraceptive across specialties.
3. Hospitals Business Unit: the anti-infectives arsenal for critical care
A direct-to-hospital business selling advanced, often patented antibiotics that tackle drug-resistant infections - the kind of medicines where the alternative is often death.
- The workhorse is a market leader in its niche - Zavicefta, a patented combination antibiotic for hospital-acquired pneumonia and complicated urinary and abdominal infections, is a market leader in its category and had already saved over 50,000 patients by FY22.
- A new weapon against superbugs - Emblaveo, launched in October 2025, targets infections caused by metallo-β-lactamase-producing pathogens, a class of multidrug-resistant Gram-negative bacteria for which treatment options are severely limited.
- Antibiotic stewardship is part of the product - the unit runs the KNOW AMR initiative to promote responsible antibiotic use, and its #PledgeWithPfizer campaign earned a Guinness World Record for the largest online video album of healthcare oaths, with over 11,000 participants. The ATLAS global surveillance programme monitors resistance patterns across 10 Indian hospital sites.
4. Inflammation & Immunology: the biologics bet on autoimmune disease
A small, specialist vertical selling high-science biologic and oral therapies to rheumatologists and dermatologists - built on a two-decade-old blockbuster and a newer, India-specific affordable alternative.
- The anchor is a proven biologic - Enbrel, a TNF inhibitor for rheumatoid arthritis, psoriasis, and related conditions, has over 20 years of clinical use, more than 500 clinical trials behind it, and has treated over 6 million patients worldwide.
- An India-specific oral option drives access - Betrecep, a JAK inhibitor launched in July 2023 as an affordability initiative, climbed to sixth rank in a market of over 85 brands within three years, supported by engagement with over 250 national Key Opinion Leaders.
Manufacturing and supply chain
One owned plant in Goa plus 18 contract manufacturers produce 6.8 billion pills and vials a year, with three-quarters of raw materials sourced locally.
- The Goa plant is the in-house engine - established in 2002, it produces 186 million Standard Dosage Units (SDUs) annually across 25 SKUs and 18 products, and was the first site across Pfizer’s entire global supply network to achieve full IMEx certification, the company’s internal production-system standard.
- Contract manufacturers handle the rest - 18 partner sites produce 1.94 billion units annually across 70 SKUs, including top brands like Becosules, Gelusil, and Corex DX.
- Distribution reaches deep - 15 warehousing partners provide 3 lakh square feet of space and handle 35,000 to 38,000 transactions a month, feeding a network of over 7,500 stockists and 2,100 institutions.
- The plant runs increasingly on sunlight - a 1,500 kWp solar installation at Goa generated roughly 2,580 MWh of clean energy in FY26, meeting about 49% of the site’s total energy needs, while the site maintains Zero Waste to Landfill and Zero Liquid Discharge status.
Group structure and partners
A subsidiary of Pfizer Inc. with no subsidiaries of its own, increasingly using commercial partnerships - not acquisitions - to expand reach for its established brands.
- The ultimate holding company is Pfizer Inc., USA, with intermediate holding entities in the Netherlands, the US, and the UK. Pfizer Ltd itself has no subsidiaries, associates, or joint ventures.
- The Becosules portfolio and other consumer-facing brands are managed through a technology-enabled distribution partnership with GoApptiv, a model designed to improve penetration without adding field-force headcount.
- The company has been simplifying its asset base: it sold its Upjohn portfolio of six off-patent brands to Mylan in 2022 for ₹180.48 Crore, transferred its Thane manufacturing facility in 2023 for ₹178 Crore, and has received MIDC approval and will take steps to complete the sale of leasehold rights and buildings on its Turbhe land to Zoetis for ₹264.40 Crore.